Drug Trial Radar · NCT05107674
A Study of NX-1607 in Adults With Advanced Malignancies
Last checked: Nov 19, 2026Latest source record: Sep 9, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
345
Planned (sponsor's estimate)
Start
Sep 29, 2021
Primary completion
Aug 31, 2026
Study completion Feb 28, 2028
Sponsor
- Lead sponsor
- Nurix Therapeutics, Inc.Industry
- Sponsor type
- Industry
- First posted
- Nov 4, 2021
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a first-in-human Phase 1a/1b multicenter, open-label oncology study designed to evaluate the safety and anti-cancer activity of NX-1607 in patients with advanced malignancies.
Conditions
- Ovarian Cancer, Epithelial
- Gastric Cancer
- GastroEsophageal Junction (GEJ) Cancer
- Head and Neck Squamous Cell Carcinoma
- Metastatic or Unresectable Melanoma
- Non-small Cell Lung Cancer (NSCLC)
- Metastatic Castration-resistant Prostate Cancer (mCRPC)
- Malignant Pleural Mesothelioma (MPM)
- Triple Negative Breast Cancer (TNBC)
- Metastatic Urothelial Carcinoma
- Cervical Cancer
- Diffuse Large B Cell Lymphoma (DLBCL)
- Richter Transformation
- Microsatellite Stable Colorectal Carcinoma
Interventions
NX-1607Drug
Oral NX-1607
PaclitaxelDrug
Paclitaxel IV
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of treatment-emergent adverse events (TEAEs), including Grade ≥ 3 TEAEs, treatment-emergent serious adverse events (SAEs), TEAEs leading to study drug discontinuation, and deaths due to TEAEsTime frame: 16 months
- Incidence of immune-related AEs (irAEs), all deaths, and dose-limiting toxicities (DLTs)Time frame: Up to 2 Years
- Objective Response Rate (ORR) per disease-specific response criteria as assessed by the InvestigatorTime frame: Up to 3 Years
Locations
17 sites in 2 countries. Site status is shown where the registry gives one.
City of Hope
Duarte, California · Completed
University of Southern California
Los Angeles, California · Recruiting
University of California, San Francisco
San Francisco, California · Recruiting
University of Colorado School of Medicine
Aurora, Colorado · Recruiting
University of Chicago
Chicago, Illinois · Recruiting
University of North Carolina
Chapel Hill, North Carolina · Recruiting
University of Oklahoma
Oklahoma City, Oklahoma · Recruiting
MD Anderson Cancer Center
Houston, Texas · Recruiting
University of Virginia
Charlottesville, Virginia · Recruiting
Fred Hutchinson Cancer Center
Seattle, Washington · Recruiting
Addenbrookes Cambridge University Hospital
Cambridge, United Kingdom · Recruiting
Beatson West of Scotland Cancer Centre
Glasgow, United Kingdom · Recruiting
Sarah Cannon Research Institute
London, United Kingdom · Recruiting
The Christie NHS Foundation Trust
Manchester, United Kingdom · Recruiting
Northern Centre for Cancer Care
Newcastle, United Kingdom · Recruiting
Churchill Hospital
Oxford, United Kingdom · Completed
Royal Marsden Hospital NHS Foundation Trust
Sutton, Surrey, United Kingdom · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.